Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TLRY
TLRY logo

TLRY Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
4.450
Open
4.450
VWAP
4.34
Vol
3.43M
Mkt Cap
532.10M
Low
4.260
Amount
14.90M
EV/EBITDA(TTM)
30.51
Total Shares
123.46M
EV
583.47M
EV/OCF(TTM)
--
P/S(TTM)
0.54
Tilray Brands, Inc. is a lifestyle consumer products company, which focuses on providing research-backed medical cannabis products to physicians, pharmacies, and patients around the world. The Company operates in four segments, which include cannabis operations, which encompasses the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. Beverage operations, which encompasses the production, marketing, and sale of beverage products. Distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers, and Wellness products, which encompasses wellness and better-for-you foods and beverages. It offers a portfolio of brands and products across medical and adult-use cannabis, craft beer, spirits, beverages, and hemp foods. It also owns digital healthcare and patient engagement platform, focused on medical cannabis education, physician consultations, and patient support services.
Show More

Events Timeline

(ET)
2026-07-07
09:00:00
Starfighters Space Borrow Rate Increases to 116.23%
select
2026-06-29 (ET)
2026-06-29
17:30:00
Tilray Acquires HelloMD to Expand Medical Cannabis Business
select
2026-04-23 (ET)
2026-04-23
13:10:00
Roth Capital: Cannabis Products Rescheduled to Schedule 3
select
2026-04-23
10:30:00
Trump Orders Medical Marijuana Products to Schedule III
select
2026-04-23
10:00:00
Trump Signs Order to Reschedule Medical Marijuana to Schedule III
select
link
2026-04-22 (ET)
2026-04-22
12:00:00
Trump Administration Expected to Reclassify Cannabis on Wednesday
select
link

News

Yahoo Finance
7.5
07-06Yahoo Finance
Tilray Expands Medical Cannabis Platform with HelloMD Acquisition
  • Tilray Acquires HelloMD: Tilray Brands strengthens its medical cannabis business by acquiring HelloMD, aiming to enhance patient access and education through a digital platform, which is expected to bolster its competitive position in the global medical cannabis market.
  • Vireo Expands into Pennsylvania: Vireo Growth signs an agreement with Hive Holdings to acquire a retail license for approximately $20 million, allowing the establishment of up to six medical cannabis dispensaries in Pennsylvania, further expanding its footprint in the U.S. market.
  • Optimi Health Export: Optimi Health completes its third commercial shipment of 1,000 capsules of 5mg psilocybin to Australia, reflecting growing demand for psychedelic treatments for treatment-resistant depression in the country.
  • Helus Pharma Financials: Helus Pharma reports a fiscal year 2026 loss of $4.25 per share, widening from the previous year, yet its lead candidate HLP003 is progressing towards a pivotal Phase 3 trial, indicating ongoing investment potential in the biotech sector.
Fool
7.5
07-03Fool
Tilray Brands Faces Significant Challenges Ahead
  • Stock Price Decline: Tilray has seen its stock price drop over 90% in the past five years, currently trading just under $5 per share, indicating significant uncertainty in the market and a lack of investor confidence.
  • Poor Financial Performance: Despite being a leader in the Canadian recreational cannabis market, Tilray has struggled with subpar organic revenue growth and remains unprofitable, reflecting competitive pressures and challenges within the industry.
  • Business Diversification Progress: In recent years, Tilray has significantly diversified its operations, becoming the fourth-largest craft brewer in the U.S. and venturing into hemp-based wellness products and pharmaceuticals, aiming to reduce reliance on recreational cannabis and enhance market competitiveness.
  • Regulatory Change Opportunities: The U.S. FDA's reclassification of certain cannabis products as Schedule III substances may open new opportunities for Tilray in medical research, although stringent regulations continue to limit market potential and competition remains fierce.
NASDAQ.COM
9.5
07-03NASDAQ.COM
Tilray Faces Uncertain Outlook Amid Challenges
  • Significant Stock Decline: Tilray's stock has plummeted over 90% in the past five years, currently trading near $5, indicating high uncertainty about its future, prompting investors to carefully assess its investment potential.
  • Diversified Business Development: While Tilray leads the Canadian recreational cannabis market, its financial performance has been poor; the company has diversified into craft brewing, hemp-based wellness products, and pharmaceuticals to reduce reliance on recreational cannabis.
  • Potential Opportunities from Regulatory Changes: The FDA's reclassification of certain cannabis products as Schedule III substances could open new avenues for Tilray in medical research, although stringent regulations still limit market potential.
  • Increased Competitive Risks: Even with a more favorable market environment, Tilray faces pressure from well-capitalized competitors, and analysts suggest investors consider more profitable companies like Green Thumb Industries, indicating limited investment appeal for Tilray.
Yahoo Finance
2.0
07-03Yahoo Finance
Tilray Brands Faces Potential Value Trap Risks
  • Stock Price Decline: Tilray has seen its stock price plummet over 90% in the past five years, currently trading just under $5 per share, indicating a severe loss of market confidence that investors should carefully assess for future potential.
  • Poor Financial Performance: Despite being a leader in the Canadian recreational cannabis market, Tilray has struggled with subpar organic revenue growth and ongoing losses, reflecting the company's difficulties in achieving profitability in a highly competitive environment.
  • Diversification Progress: Tilray has significantly diversified its business, becoming the fourth-largest craft brewer in the U.S. and venturing into hemp-based wellness products and pharmaceuticals; however, its financial results have not shown consistent improvement, highlighting the challenges of transformation.
  • Regulatory Change Opportunities: The U.S. FDA's reclassification of certain cannabis products as Schedule III substances may provide Tilray with opportunities in medical research, yet stringent regulations and competitive pressures within the industry could still limit its market potential.
Newsfilter
8.5
06-30Newsfilter
Breckenridge Distillery Wins Multiple International Awards
  • International Award Recognition: Breckenridge Distillery secured a Double Gold at the 17th New York International Spirits Competition, with Rum Cask Finish scoring 96 points, showcasing its exceptional quality and competitiveness in the global spirits market.
  • Distillery of the Year: The distillery was named Colorado Distillery of the Year for 2026 at the NYISC, marking its sixth win and further solidifying its leadership position within the industry.
  • Multiple Award-Winning Products: In addition to Rum Cask Finish, Breckenridge Cognac Cask Finish Whiskey, Peat Fetish, Vodka, and Casa Breck Tequila Blanco also earned Gold medals with scores of 95 points, highlighting the distillery's diverse product line and high-level craftsmanship.
  • Enhanced Market Influence: With Rum Cask Finish achieving back-to-back Double Golds at both the San Francisco World Spirits Competition and NYISC, Breckenridge Distillery's brand influence and market share are expected to increase, attracting more consumer attention to its innovative and high-quality spirits offerings.
seekingalpha
8.5
06-29seekingalpha
Tilray Acquires Digital Health Platform HelloMD
  • Acquisition Deal: Tilray Brands has acquired the digital health platform HelloMD for an undisclosed amount, a move that is expected to significantly enhance Tilray's position in the global medical cannabis market.
  • Platform Strength: As a leading digital healthcare and patient engagement platform, HelloMD focuses on medical cannabis education, physician consultations, and patient support services, which will boost Tilray's direct-to-patient capabilities.
  • Education and Engagement: This acquisition will enhance Tilray's ability to educate physicians and patients, deepening patient engagement throughout the care journey, thereby driving long-term growth in the medical cannabis sector.
  • Market Outlook: While Tilray demonstrates strong synergies post-acquisition, the overall cannabis industry remains challenged, prompting investors to monitor market dynamics to assess future performance.
Wall Street analysts forecast TLRY stock price to rise
4 Analyst Rating
Wall Street analysts forecast TLRY stock price to rise
1 Buy
3 Hold
0 Sell
Hold
Current: 0.000
sliders
Low
8.50
Averages
9.57
High
10.00
Current: 0.000
sliders
Low
8.50
Averages
9.57
High
10.00
Canaccord
Hold
downgrade
$13
AI Analysis
2026-04-02
Reason
Canaccord
Price Target
$13
AI Analysis
2026-04-02
downgrade
Hold
Reason
Canaccord lowered the firm's price target on Tilray to C$9.50 from C$13 and keeps a Hold rating on the shares.
Roth Capital
Bill Kirk
Neutral
to
Buy
upgrade
$10
2026-04-01
Reason
Roth Capital
Bill Kirk
Price Target
$10
2026-04-01
upgrade
Neutral
to
Buy
Reason
Roth Capital analyst Bill Kirk upgraded Tilray to Buy from Neutral with an unchanged $10 price target. The firm is citing the company's core Canadian business holding steady, inflection in Tilray's international operations and improving beverage category, the analyst tells investors in a research note. Tilray shares are back at July 2025 levels, but the fundamental outlook has improved and the potential for regulatory change is greater, the firm added.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TLRY
Unlock Now

Valuation Metrics

The current forward P/E ratio for Tilray Brands Inc (TLRY.O) is 1000.00, compared to its 5-year average forward P/E of 94.65. For a more detailed relative valuation and DCF analysis to assess Tilray Brands Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
94.65
Current PE
1000.00
Overvalued PE
435.43
Undervalued PE
-246.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
31.37
Current EV/EBITDA
-1.46
Overvalued EV/EBITDA
62.67
Undervalued EV/EBITDA
0.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.63
Current PS
0.52
Overvalued PS
4.97
Undervalued PS
0.29

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

how is cannibis securities doing today
Intellectia · 8 candidates
Market Cap: >= 100.00MPrice: >= $1.00Themes: The Cannabis IndustryMonthly Average Dollar Volume: >= 200,000
Ticker
Name
Market Cap$
top bottom
CGC logo
CGC
Canopy Growth Corp
511.04M
TLRY logo
TLRY
Tilray Brands Inc
803.02M
SNDL logo
SNDL
SNDL Inc
391.39M
VFF logo
VFF
Village Farms International Inc
328.97M
ACB logo
ACB
Aurora Cannabis Inc
201.89M
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.49B
best day trade stock
Intellectia · 9 candidates
Price: $5.00 - $100.00Volume: >= 3,000,000Price Change Pct: >= $3.00Relative Vol: >= 2Beta: HighRisk
Ticker
Name
Market Cap$
top bottom
KODK logo
KODK
Eastman Kodak Co
1.10B
ORIC logo
ORIC
Oric Pharmaceuticals Inc
995.75M
LUNR logo
LUNR
Intuitive Machines Inc
5.20B
RLAY logo
RLAY
Relay Therapeutics Inc
2.24B
GSAT logo
GSAT
Globalstar Inc
10.00B
AEHR logo
AEHR
Aehr Test Systems
1.36B
what penny stocks to buy pre market 4/1/26
Intellectia · 14 candidates
Market Cap: 100.00M - 2.00BRegion: USVolume: >= 200,000Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEPre Market Price Change: $3.00 - $20.00
Ticker
Name
Market Cap$
top bottom
TLRY logo
TLRY
Tilray Brands Inc
753.80M
OMER logo
OMER
Omeros Corp
748.71M
VOR logo
VOR
Vor Biopharma Inc
871.44M
VALN logo
VALN
Valneva SE
542.98M
SLNO logo
SLNO
Soleno Therapeutics Inc
1.73B
SGMO logo
SGMO
Sangamo Therapeutics Inc
102.28M
Give me the top 5 cannabis companies
Intellectia · 4 candidates
Market Cap: >= 500.00MRevenue Ttm: >= 100.00MRegion: USThemes: The Cannabis IndustryList Exchange: XNYS, XNAS, XASEIs Optionable: TrueMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.52B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.43B
CRON logo
CRON
Cronos Group Inc
947.63M
TLRY logo
TLRY
Tilray Brands Inc
736.32M
Should I Buy cannabis stocks?
Intellectia · 9 candidates
Market Cap: >= 50.00MThemes: The Cannabis IndustryList Exchange: XNYS, XNASMonthly Average Dollar Volume: >= 100,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
4.06B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.29B
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
CGC logo
CGC
Canopy Growth Corp
440.50M
SNDL logo
SNDL
SNDL Inc
386.25M
what cannabis stocks would you buy?
Intellectia · 4 candidates
Market Cap: >= 200.00MPrice: >= $1.00Themes: The Cannabis IndustryQuarter Revenue Yoy Growth: >= 0.0%Monthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
SNDL logo
SNDL
SNDL Inc
386.25M
ACB logo
ACB
Aurora Cannabis Inc
204.15M
cannabis
Intellectia · 8 candidates
Market Cap: >= 200.00MPrice: >= $1.00Themes: The Cannabis IndustryIs Optionable: TrueMonthly Average Dollar Volume: >= 200,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
4.06B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.29B
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
CGC logo
CGC
Canopy Growth Corp
440.50M
SNDL logo
SNDL
SNDL Inc
386.25M
marijuana stocks
Intellectia · 8 candidates
Market Cap: >= 200.00MRegion: US, CanadaPrice: >= $1.00Themes: The Cannabis IndustryList Exchange: XNYS, XNAS, XASEIs Optionable: TrueMonthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.70B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.41B
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M
CGC logo
CGC
Canopy Growth Corp
460.70M
SNDL logo
SNDL
SNDL Inc
406.85M
which. cannabisindustry should I invest in
Intellectia · 2 candidates
Market Cap: >= 500.00MThemes: The Cannabis IndustryWeekly Average Turnover: >= 1,000,000Annual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M
Cannibus stocks
Intellectia · 4 candidates
Market Cap: >= 500.00MThemes: The Cannabis IndustryBeta: ModerateRisk, HighRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.70B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.41B
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M

Whales Holding TLRY

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Tilray Brands Inc (TLRY) stock price today?

The current price of TLRY is 4.31 USD — it has decreased -1.6

What is Tilray Brands Inc (TLRY)'s business?

Tilray Brands, Inc. is a lifestyle consumer products company, which focuses on providing research-backed medical cannabis products to physicians, pharmacies, and patients around the world. The Company operates in four segments, which include cannabis operations, which encompasses the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. Beverage operations, which encompasses the production, marketing, and sale of beverage products. Distribution operations, which encompasses the purchase and resale of pharmaceutical products to customers, and Wellness products, which encompasses wellness and better-for-you foods and beverages. It offers a portfolio of brands and products across medical and adult-use cannabis, craft beer, spirits, beverages, and hemp foods. It also owns digital healthcare and patient engagement platform, focused on medical cannabis education, physician consultations, and patient support services.

What is the price predicton of TLRY Stock?

Wall Street analysts forecast TLRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is9.57 USD with a low forecast of 8.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Tilray Brands Inc (TLRY)'s revenue for the last quarter?

Tilray Brands Inc revenue for the last quarter amounts to 206.73M USD, increased 11.28

What is Tilray Brands Inc (TLRY)'s earnings per share (EPS) for the last quarter?

Tilray Brands Inc. EPS for the last quarter amounts to -0.24 USD, decreased -97.24

How many employees does Tilray Brands Inc (TLRY). have?

Tilray Brands Inc (TLRY) has 2842 emplpoyees as of July 08 2026.

What is Tilray Brands Inc (TLRY) market cap?

Today TLRY has the market capitalization of 532.10M USD.